Andrew Rowland, PhD

Flinders Center for Innovation in Cancer, Flinders University, Adelaide, Australia

Dr Rowland is an analytical chemist and trialist with a research focus on the advancement of precision medicine approaches such that they translate to direct improvements for oncology patients by facilitating the maximal therapeutic benefit from targeted anti-cancer medicines, while minimising the harmful effects of these drugs. 

Dr Rowland completed a PhD clinical pharmacology in 2009 and is now Senior Lecturer in the School of Medicine at Flinders University. As a senior researcher within the Precision Medicines Group at Flinders Center for Innovation in Cancer, Dr Rowland oversees projects and trials that cover a spectrum from basic laboratory research to interpretation of multicentre clinical trial data. Dr Rowland has authored multiple Web of Science highly cited manuscripts, and his recent work in the field of colorectal cancer has informed the prestigious NCCN guidelines for this malignancy in regard to predictive genetic markers of treatment response to anti-EGFR monoclonal antibodies.